Manager TitleAgeSince
Chief Executive Officer 47 01/03/2016
President 69 01/10/2016
Chief Tech/Sci/R&D Officer 69 01/06/2016
Director TitleAgeSince
Director/Board Member - 26/01/2021
Date Insider Type Main position Quantity % Market Cap.
26/01/21 Issuer sale

Director

25,973 0.0668%
26/01/21 Issuer sale

Director

25,973 0.0668%
26/01/21 Don

Chief Technology Officer

366,525 0.9431%
Change 5-day change 1-year change 3-year change Capi.($)
-4.85%-4.63% - - 4.75B
-3.42%+4.90%+61.15%+87.70% 55.98B
-0.48%-2.28%+52.08%+70.57% 53.69B
+1.56%-5.20%+5.21%+429.47% 23.29B
+0.04%-0.01%-17.61%-14.67% 23.15B
-5.95%-2.58%+30.67%-9.47% 20.58B
-0.94%+0.40%+32.07%-30.16% 17.76B
-4.55%-1.95%+192.65%+349.58% 16.09B
-6.91%-5.83%+26.53%+644.30% 15.93B
+0.04%-1.46%+24.08%+190.13% 14B
Average -2.56%-0.43%+45.20%+190.83% 26.72B
Weighted average by Cap. -2.15%-0.88%+45.72%+150.46%
Logo Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.
Employees
-
  1. Stock Market
  2. Stocks
  3. EIDX Stock